BOT 1.33% 37.0¢ botanix pharmaceuticals ltd

Ann: FDA Approves Sofdra, page-150

  1. 986 Posts.
    lightbulb Created with Sketch. 156
    CU6 and DXB more than doubled witihin 2 months of a CR post a PH3/FDA catalysts... IMO BOT SP to at least double from here if not triple SP within 2-6 months, then blue skys... based on quarterlys and other pipeline drugs... BOD should consider finishing up ACNE...PH3, that will uplift the market cap/SP substansially.

    CU6 raised on 26/3/24
    https://hotcopper.com.au/data/attachments/6258/6258352-2113324a36ee8fba725efd17612563ca.jpg

    DXB raised on 12/3/24
    https://hotcopper.com.au/data/attachments/6258/6258396-6f23b637a8faa10662fa08e0b14369ca.jpg




 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.